Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $1.1 million.

  • Akebia Therapeutics' Cash from Financing Activities fell 899.43% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.1 million, marking a year-over-year increase of 28429.05%. This contributed to the annual value of $49.7 million for FY2024, which is 29702.85% up from last year.
  • Akebia Therapeutics' Cash from Financing Activities amounted to $1.1 million in Q3 2025, which was down 899.43% from $1.7 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Cash from Financing Activities high stood at $74.9 million for Q1 2025, and its period low was -$32.9 million during Q3 2022.
  • Its 5-year average for Cash from Financing Activities is $13.2 million, with a median of $1.7 million in 2025.
  • Per our database at Business Quant, Akebia Therapeutics' Cash from Financing Activities plummeted by 12890000.0% in 2023 and then soared by 234600.0% in 2024.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Cash from Financing Activities stood at $5.4 million in 2021, then plummeted by 100.02% to -$1000.0 in 2022, then plummeted by 128900.0% to -$1.3 million in 2023, then surged by 1830.62% to $22.3 million in 2024, then plummeted by 95.01% to $1.1 million in 2025.
  • Its Cash from Financing Activities stands at $1.1 million for Q3 2025, versus $1.7 million for Q2 2025 and $74.9 million for Q1 2025.